Acadia Pharmaceuticals (ACAD) Q3 FY2026 earnings: revenue $342 million, up 22.8% on the year

Acadia Pharmaceuticals Inc. (ACAD) reported revenue of $342 million for Q3 FY2026, the quarter ended 30 September 2026, up 22.8% on the same quarter a year earlier. Net income was $54 million, down 25.4% on the year, and diluted earnings per share $0.31. The figures are the company's own, from the 10-Q it filed with the SEC on 5 November 2026.

Revenue

$342 million

+22.8% on the year · +11.1% on the quarter

Q4 FY2024Q3 FY2026

Operating margin

21.0%

12.8% a year earlier

Q4 FY2024Q3 FY2026

Net income

$54 million

-25.4% on the year · +69.9% on the quarter

Q4 FY2024Q3 FY2026

Diluted EPS

$0.31

-26.2% on the year · +72.2% on the quarter

Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 1 raised, 1 lowered, 1 new.

Total revenue rose 23% to $342M: GAAP total revenues were $342 million, up 23% from $279 million. Against the non-GAAP adjusted prior-year figure of $281 million, growth was 22%.
Net income fell against prior-year tax benefit: Net income was $54 million, or $0.31 per diluted share, against $72 million, or $0.42, a year earlier. The prior-year quarter included a $27.2 million income tax benefit.
DAYBUE sales up 39% on STIX: DAYBUE net sales were $140 million, up 39% from $101 million. The release attributes the growth to uptake of DAYBUE STIX.

Read the earnings call summary

Income statement (profit and loss)

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Revenue	342	308	279	+11.1%	+22.8%
Cost of revenue	35.1	28.3	21.6	+23.9%	+62.1%
Gross profit	307	280	257	+9.9%	+19.5%
Gross margin	89.7%	90.8%	92.2%
Research and development	76.3	81.6	87.8	-6.5%	-13.1%
Selling, general and administrative	159	160	133	-0.7%	+19.3%
Operating income	71.7	37.8	35.8	+89.5%	+100.6%
Operating margin	21.0%	12.3%	12.8%
Pre-tax income	80.4	46.5	44.6	+73.1%	+80.4%
Income tax	26.9	15.0	-27.2	+79.8%
Effective tax rate	33.5%	32.2%	-61.0%
Net income	53.5	31.5	71.8	+69.9%	-25.4%
Net margin	15.6%	10.2%	25.8%
Diluted EPS	$0.31	$0.18	$0.42	+72.2%	-26.2%

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Operating cash flow	11.5	101	74.3	-88.6%	-84.5%
Capital expenditure	1.2	5.1	0.4	-75.6%	+219.6%
Free cash flow	10.3	95.7	73.9	-89.3%	-86.1%
Free cash flow margin	3.0%	31.1%	26.5%
Cash from investing	-86.2	-8.5	-79.4
Cash from financing	11.9	10.5	9.4	+13.1%	+26.0%
Depreciation and amortisation	3.7	3.2	3.0	+15.7%	+23.8%
Share-based compensation	17.4	16.9	13.2	+3.0%	+32.4%
Diluted shares, weighted	175m	173m	171m	+1.5%	+2.8%
Shares outstanding at period end	173m	172m	169m	+0.4%	+2.2%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Shareholders' equity	1,387	1,307	917	+6.2%	+51.3%
Debt	0.0	0.0	0.0
Operating lease liabilities	57.3	59.5	43.0	-3.7%	+33.2%
Other liabilities	349	377	370	-7.3%	-5.7%
Total liabilities and equity	1,794	1,743	1,331	+2.9%	+34.8%
Fixed assets	18.4	17.1	3.7	+7.6%	+396.3%
Intangible assets	135	103	112	+31.0%	+21.4%
Investments	654	571	589	+14.5%	+11.0%
Cash and equivalents	322	385	258	-16.3%	+24.9%
Receivables	161	151	116	+6.9%	+39.0%
Inventory	107	109	106	-1.7%	+0.8%
Other assets	396	407	147	-2.6%	+170.1%
Total assets	1,794	1,743	1,331	+2.9%	+34.8%

Questions

What was Acadia Pharmaceuticals' revenue in Q3 FY2026?

Acadia Pharmaceuticals (ACAD) reported revenue of $342 million for Q3 FY2026, the quarter ended 30 September 2026, up 22.8% on the same quarter a year earlier.

How much did Acadia Pharmaceuticals earn in Q3 FY2026?

Net income for Q3 FY2026 was $54 million, down 25.4% on the year, and diluted earnings per share $0.31.

When did Acadia Pharmaceuticals report Q3 FY2026 results?

Acadia Pharmaceuticals filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 5 November 2026.

Quarterly results, the last 20 quarters

	Q4 FY2021	Q1 FY2022	Q2 FY2022	Q3 FY2022	Q4 FY2022	Q1 FY2023	Q2 FY2023	Q3 FY2023	Q4 FY2023	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026	Q3 FY2026
Revenue	131	115	135	131	136	118	165	212	231	206	242	250	260	244	265	279	284	268	308	342
Cost of revenue	2.4	3.0	2.7	2.1	2.4	1.7	7.5	14.6	17.9	23.0	18.2	18.9	21.8	20.4	20.7	21.6	26.2	24.8	28.3	35.1
Gross profit	128	113	132	129	134	117	158	197	213	183	224	232	238	224	244	257	258	243	280	307
Gross margin	98%	97%	98%	98%	98%	99%	95%	93%	92%	89%	92%	92%	92%	92%	92%	92%	91%	91%	91%	90%
R&D	66.9	129	75.6	81.3	75.7	69.1	58.8	157	66.7	59.7	76.2	66.6	101	78.3	78.0	87.8	84.8	76.9	81.6	76.3
SG&A	106	96.7	89.9	78.1	104	101	96.0	97.9	111	108	117	133	130	126	134	133	156	171	160	159
Operating income	-44.7	-113	-33.7	-30.9	-46.1	-53.6	3.0	-57.8	34.9	15.2	30.4	31.6	154	19.3	32.4	35.8	17.4	-4.6	37.8	71.7
Operating margin	-34%	-98%	-25%	-24%	-34%	-45%	2%	-27%	15%	7%	13%	13%	59%	8%	12%	13%	6%	-2%	12%	21%
Pre-tax income	-42.9	-113	-33.6	-26.4	-40.9	-44.9	6.3	-52.1	39.7	21.0	37.2	38.8	161	27.8	40.2	44.6	26.3	4.0	46.5	80.4
Tax rate	n/a	n/a	n/a	n/a	n/a	n/a	82%	n/a	-15%	21%	10%	16%	11%	32%	34%	-61%	-939%	9%	32%	33%
Net income	-43.1	-113	-34.0	-27.2	-41.7	-43.0	1.1	-65.2	45.8	16.6	33.4	32.8	144	19.0	26.7	71.8	274	3.6	31.5	53.5
Net margin	-33%	-98%	-25%	-21%	-31%	-36%	1%	-31%	20%	8%	14%	13%	55%	8%	10%	26%	96%	1%	10%	16%
Diluted EPS	-$0.27	-$0.70	-$0.21	-$0.17	-$0.26	-$0.27	$0.01	-$0.40	$0.28	$0.10	$0.20	$0.20	$0.86	$0.11	$0.16	$0.42	$1.60	$0.02	$0.18	$0.31
Operating cash flow	-23.1	-76.3	-13.1	-0.7	-23.9	-17.9	8.2	-59.0	85.4	29.1	25.0	63.2	40.4	20.3	64.0	74.3	-48.7	34.0	101	11.5
Capital expenditure	0.0	0.0	0.0	0.0	0.0	n/a	n/a	n/a	n/a	n/a	n/a	0.1	n/a	0.0	0.3	0.4	4.0	5.2	5.1	1.2
Free cash flow	-23.1	-76.3	-13.1	-0.7	-23.9	n/a	n/a	n/a	n/a	n/a	n/a	63.2	n/a	20.3	63.7	73.9	-52.7	28.8	95.7	10.3
Shares outstanding	161m	161m	162m	162m	162m	162m	163m	164m	165m	165m	166m	166m	167m	167m	169m	169m	170m	171m	172m	173m
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q

Each quarter as filed, linked to its filing.

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2026, filed 5 November 2026: the filing.